Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) FCF Margin (2016 - 2025)

Lisata Therapeutics' FCF Margin history spans 11 years, with the latest figure at 3249.0% for Q4 2025.

  • For Q4 2025, FCF Margin fell 279620.0% year-over-year to 3249.0%; the TTM value through Dec 2025 reached 9398.24%, down 746264.0%, while the annual FY2025 figure was 9398.24%, 746264.0% down from the prior year.
  • FCF Margin reached 3249.0% in Q4 2025 per LSTA's latest filing, up from 5651.43% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 452.8% in Q4 2024 to a low of 5651.43% in Q2 2025.